Life science alliance · 2024
USP27X variants underlying X-linked intellectual disability disrupt protein function via distinct mechanisms.
СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Koch Intisar, Slovik Maya, Zhang Yuling, Liu Bingyu, Rennie Martin, Konz Emily, Cogne Benjamin, Daana Muhannad, Davids Laura, Diets Illja J, Gold Nina B, Holtz Alexander M, Isidor Bertrand, Mor-Shaked Hagar, Neira Fresneda Juanita, Niederhoffer Karen Y, Nizon Mathilde, Pfundt Rolph, Simon Meh, Stegmann Apa, Guillen Sacoto Maria J, Wevers Marijke, Barakat Tahsin Stefan, Yanovsky-Dagan Shira, Atanassov Boyko S, Toth Rachel, Gao Chengjiang, Bustos Francisco, Harel Tamar
Аннотация
Neurodevelopmental disorders with intellectual disability (ND/ID) are a heterogeneous group of diseases driving lifelong deficits in cognition and behavior with no definitive cure. X-linked intellectual disability disorder 105 (XLID105, #300984; OMIM) is a ND/ID driven by hemizygous variants in the USP27X gene encoding a protein deubiquitylase with a role in cell proliferation and neural development. Currently, only four genetically diagnosed individuals from two unrelated families have been described with limited clinical data. Furthermore, the mechanisms underlying the disorder are unknown. Here, we report 10 new XLID105 individuals from nine families and determine the impact of gene variants on USP27X protein function. Using a combination of clinical genetics, bioinformatics, biochemical, and cell biology approaches, we determined that XLID105 variants alter USP27X protein biology via distinct mechanisms including changes in developmentally relevant protein-protein interactions and deubiquitylating activity. Our data better define the phenotypic spectrum of XLID105 and suggest that XLID105 is driven by USP27X functional disruption. Understanding the pathogenic mechanisms of XLID105 variants will provide molecular insight into USP27X biology and may create the potential for therapy development.